UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 of 15(d) of the
Securities Exchange Act of 1934
January 3, 2011
------------------------------------------------
Date of Report (date of earliest event reported)
CYTODYN INC.
----------------------------------------------------
Exact name of Registrant as Specified in its Charter
Colorado 000-49908 75-3056237
--------------------------- --------------- ---------------------------
State or Other Jurisdiction Commission File IRS Employer Identification
of Incorporation Number Number
1511 Third Street, Santa Fe, New Mexico 87505
----------------------------------------------------------
Address of Principal Executive Offices, Including Zip Code
(505) 988-5520
--------------------------------------------------
Registrant's Telephone Number, Including Area Code
Not applicable
-----------------------------------------------------------
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 OTHER EVENTS
On January 3, 2011 the Company hired Richard Trauger, PhD. as Director of
Scientific Information.
Dr. Trauger received his Ph.D. in 1986 from the University Of South Carolina
School Of Medicine in retrovirology. After completing his post-doctoral studies
at the Scripps Research Institute in La Jolla, Dr Trauger joined The Immune
Response Corporation as Associate Director of Immunology, where he worked with
Dr. Jonas Salk on the development of an immune-based therapy for HIV infection.
In addition to his research duties, Dr. Trauger also functioned as the company's
Scientific Liaison and was the company's point of contact to the scientific,
financial and activist communities.
The Company issued a press release on January 7, 2011 (attached hereto as
Exhibit 99) regarding new hire Richard Trauger
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements of Businesses Acquired.
Not Applicable.
(b) Pro Forma Financial Information
Not Applicable.
(c) Shell Company Transactions
Not Applicable.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTODYN INC.
Date: January 7, 2011 By: /s/ Kenneth J. Van Ness
------------------------------
Kenneth J. Van Ness
President and CEO